Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myelin oligodendrocyte glycoprotein-reactive autoreactive effector and memory CD4+ and/or CD8+ T cells are populations of T lymphocytes that recognize antigens derived from myelin oligodendrocyte glycoprotein (MOG), a protein found on the outer surface of central nervous system myelin[2][3][6]. These T cells escape central and peripheral tolerance, become activated, and contribute to demyelination by attacking CNS myelin, either directly (by cytotoxicity or cytokine secretion) or indirectly by promoting recruitment of other inflammatory cells and facilitating entry of antibodies and immune mediators[2][4]. They are central to animal models of experimental autoimmune encephalomyelitis and play a pathogenic role in multiple human demyelinating diseases including MS and MOGAD, with CD4+ T cells generally having a dominant role but CD8+ T cells also being involved[1][2][6].
Suppression of T cell proliferation or function; Depletion of immune cells; Modulation of antibody production
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myelin oligodendrocyte glycoprotein-reactive autoreactive effector memory T cell (null).